Updated on 11 August 2026
2Health AI
CEO at Gene to Health Limited
China (Hong Kong)
About
Gene to Health Limited (https://gene2h.com) have launched the G2H system embodying broad-spectrum disease-risk prediction models trained on health data from over one million people, which integrates DNA data, health check reports, and medical records to generate risk scores for over a thousand diseases. Its spin-off, 2Health AI Limited (https://2health.cn), has recently developed the world's first comprehensive multi-omics and AI-driven personal health digital twin platform, 2HEALTH AI (2HAI). It integrates genomic, metabolomic, physical-exam, clinical, wearable, home-device and lifestyle data into a continuously-updated personal health profile spanning the entire life cycle. Powered by the G2H system, plus an intelligent analytics engine and AI health advisors, 2HAI delivers lifelong health-data management, long-term risk assessment across hundreds of diseases, personalized recommendations, secondary report interpretation, lifestyle intervention, biological-age and life-expectancy estimation, and connection to medical services. The platform offer interfaces also to doctors and suppliers, helping connect them with individuals and families in a large ecosystem of healthcare products and services. The platform is already live at 2health.ai and is being put into pilot use as Digital Public Infrastructure for Health (DPI-H) in the ASEAN market.
Project Location
- China (Hong Kong)
Project Website
https://2health.cn
Project Format
- Public-Private Partnership Project
Go Global Project
- No
ESG (Environmental, Social, and Governance)
- Yes
Project Stage
- Investment / Financing Discussion
Main Project Sector
- Public Utilities
- Technology
Public Utilities
- ICT And Data Center
Technology
- Bio-Tech
- Fin-Tech
- Health Technology
- Medical Technology
Total Project Value
- 1,000,001 to 2,500,000 USD
Investment Capital Required
- 2,500,001 to 5,000,000 USD
Interested Format of Cooperation
- Direct Equity Investment
- Joint Venture
Preferred Financing Model
- Equity
Type(s) of Last Financing Round of the project (if Applicable)
- Venture Capital (VC)
Main Service(s) Required
- Financial Services
Financial Services
- Investment Banking
- Private Equity & Venture Capital
Professional Services
- Business Valuation
Attached files
Organisation
China (Hong Kong)
Similar opportunities
Project
- No
- Yes
- Equity
- Technology
- Private Project
- Private Banking
- Health Technology
- Equity (private)
- Medical Technology
- Financial Services
- Investment Banking
- Mergers & Acquisition
- Direct Equity Investment
- 2,500,001 to 5,000,000 USD
- 7,500,001 to 10,000,000 USD
- Private Equity & Venture Capital
- Investment / Financing Discussion
Avi Lior
CEO at Therapnea Labs PLC
Cyprus
Project
AI enabled Acceleration of Preclinical Biologic Drug Development
- No
- Yes
- Equity
- Bio-Tech
- Technology
- Private Project
- Equity (private)
- Financial Services
- Partner Identification
- Direct Equity Investment
- 10,000,001 to 25,000,000 USD
- Private Equity & Venture Capital
Kingsley Leung
Chairman & Co-founder at Great Bay Bio Limited
China (Hong Kong)
Project
- No
- Yes
- Equity
- Technology
- Joint Venture
- Private Project
- Health Technology
- Equity (private)
- Medical Technology
- Open for Negotiation
- Direct Equity Investment
- 2,500,001 to 5,000,000 USD
- 1,000,001 to 2,500,000 USD
- Information Technology Services
- Private Equity & Venture Capital
- Investment / Financing Discussion
Cameron Ho
Medical & Healthcare AI at 0xmd Inc.
China (Hong Kong)